ProCE Banner Activity

Case Discussion: Investigating Approved Therapies in New Settings in mCRPC

Slideset Download
Download these slides from a live symposium to learn more about therapeutic strategies combining already approved therapies in mCRPC

Released: February 18, 2022

Expiration: February 17, 2023

Share

Faculty

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Novartis Pharmaceuticals Corp Advanced Accelerator Applications

Sanofi Genzyme

Faculty Disclosure

Primary Author

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Rana R. McKay, MD, has disclosed that she has received consultant/advisor/speaker fees from AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento, and Tempus.